Literature DB >> 24102220

Antimicrobial susceptibilities and distribution of sequence types of Neisseria gonorrhoeae isolates in Canada: 2010.

Irene Martin1, Pam Sawatzky, Gary Liu, Vanessa Allen, Brigitte Lefebvre, Linda Hoang, Marguerite Lovgren, David Haldane, Paul Van Caeseele, Greg Horsman, Richard Garceau, Sam Ratnam, Tom Wong, Matthew Gilmour.   

Abstract

The monitoring of antimicrobial susceptibilities in Neisseria gonorrhoeae isolates and characterization of N. gonorrhoeae multiantigen sequence types (NG-MAST, ST) provide important surveillance data as resistance rates continue to rise. A total of 2970 N. gonorrhoeae isolates were collected by Canadian provincial public health laboratories in 2010, and 1233 were submitted to the National Microbiology Laboratory for testing. The NG-MAST and minimum inhibitory concentration (MIC) by agar dilution were determined for each isolate. Of the 2970 isolates, 25.1% were resistant to penicillin, 34.6% resistant to tetracycline, 31.5% resistant to erythromycin, 35.9% resistant to ciprofloxacin, and 1.2% resistant to azithromycin. Decreased susceptibility to cefixime (MIC ≥ 0.25 mg/L) and ceftriaxone (MIC ≥ 0.125 mg/L) was identified in 3.2% and 7.3% of the isolates, respectively. The most common STs found in Canada were ST1407 (13.3%), ST3150 (11.3%), and ST3158 (9.0%), with 249 different STs identified among the isolates. Within the ST1407 group, 19.5% and 43.3% isolates have decreased susceptibility to cefixime and ceftriaxone, respectively. ST1407, the most prevalent NG-MAST in Canada in 2010, has been associated with high-level ceftriaxone MICs and with cefixime treatment failure cases worldwide. Identification and monitoring of STs and corresponding antimicrobial resistance profiles may be useful in surveillance programs and be used to inform public health actions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24102220     DOI: 10.1139/cjm-2013-0357

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  5 in total

1.  Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.

Authors:  Richard A Alm; Sushmita D Lahiri; Amy Kutschke; Linda G Otterson; Robert E McLaughlin; James D Whiteaker; Lisa A Lewis; Xiaohong Su; Michael D Huband; Humphrey Gardner; John P Mueller
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

2.  Twenty-five-year changing pattern of gonococcal antimicrobial susceptibility in Shanghai: surveillance and its impact on treatment guidelines.

Authors:  Wei-Ming Gu; Yue Chen; Yang Yang; Lei Wu; Wei-Zhong Hu; Yue-Lan Jin
Journal:  BMC Infect Dis       Date:  2014-12-30       Impact factor: 3.090

3.  Characterization of Neisseria gonorrhoeae isolates detected in Switzerland (1998-2012): emergence of multidrug-resistant clones less susceptible to cephalosporins.

Authors:  Andrea Endimiani; Yuvia N Guilarte; Regula Tinguely; Lea Hirzberger; Sylvia Selvini; Agnese Lupo; Christoph Hauser; Hansjakob Furrer
Journal:  BMC Infect Dis       Date:  2014-02-25       Impact factor: 3.090

4.  Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011-2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone.

Authors:  Sai Li; Xiao-Hong Su; Wen-Jing Le; Fa-Xing Jiang; Bao-Xi Wang; Peter A Rice
Journal:  BMC Infect Dis       Date:  2014-11-27       Impact factor: 3.090

5.  Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.

Authors:  Anthony D Cristillo; Claire C Bristow; Elizabeth Torrone; Jo-Anne Dillon; Robert D Kirkcaldy; Huan Dong; Yonatan H Grad; Robert A Nicholas; Peter A Rice; Kenneth Lawrence; David Oldach; William Maurice Shafer; Pei Zhou; Teodora E Wi; Sheldon R Morris; Jeffrey D Klausner
Journal:  Sex Transm Dis       Date:  2019-03       Impact factor: 2.830

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.